WeedLife News Network

Canada-based dispensaries and brands can now use Surfside's leading cannabis advertising platform to grow their business

Surfside Solutions Inc. ("Surfside"), an end-to-end marketing technology that aggregates first-party data across all customer touchpoints, today announced the general availability of the Surfside Platform to Canadian dispensaries and brands. By combining the power of a customer data platform (CDP) and a demand side platform (DSP), Surfside provides an all-in-one solution for cannabis businesses looking to activate customer data by advertising to new and existing customers across websites and mobile apps.

"Surfside has been a great advertising partner for our business," says Will Alexander, head of marketing at Burb, a British Columbia-based dispensary chain and cannabis brand.

"By giving us the ability to advertise to local cannabis consumers with digital ads and track the results for both ecommerce and in-store sales, Surfside helps make sure that every ad dollar we spend is helping us grow."

With the Surfside Platform, cannabis businesses can:

"We have been building our presence and capabilities in Canada through a series of partnerships and campaigns over the last twelve months and we can't wait to start helping more Canadian clients grow as we invest more heavily into this important market," says Travis Scadron, VP of Business Development at Surfside.

We are pleased to announce that Aphios® Pharma LLC will host a live webinar followed by Q&A on the business of cannabis as a pharmaceutical medicine.

This webinar will cover the business of cannabis as a pharmaceutical medicine, touching on the business of cannabis in recreational and medical use. We will show you our competitors and competitive advantages in the pharmaceutical marketplace. We will present estimates of the total and accessible marketplaces for our first-generation products targeting generalized social anxiety disorder (GSAD), chemotherapy induced peripheral neuropathic pain (CIPNP), opioid use disorder (OUD), and pain and spasticity associated with Multiple Sclerosis (PSAMS). We will then layout our product development plans and commercialization strategies for each identified segment of our market. The webinar will close with investment, financing and exit strategies.

Join Aphios® Pharma founder and CEO Dr. Trevor P. Castor, along with guests Dr. Val R. Livada, Business Advisor and Controller Catherine Prillo, on July 14, 2022, from 12 pm to 12:45 pm EST, for a discussion on the financial aspects of cannabis as a medicine and the drug-delivery nanotechnologies that make cannabis more effective.

Ubiquitech Software Corp. (OTC PINK:UBQU), through its operating subsidiary CannazALL™ is pleased to announce its new and improved Affiliate marketing program designed to increase sales of its popular hemp derived CBD products.

The new Affiliate Program at allows virtually any size Affiliate to spread the word about CannazALL™ CBD products and earn money when a referral is converted into a sale. The Company announced on December 21, 2021, that it had over 1,000 registered Affiliates and the Company is now poised to register an additional 1,000, or more, this year.

CEO James Ballas said "We are seeking to incorporate more Affiliates into the CannazALL™ program as it's one of the most cost-effective ways to obtain a new customer and keep ad costs under control. Through the end of this year and into 2023 we expect to dramatically increase the number of qualified Affiliates that can really bring in the sales"

The Company utilizes colorful and enticing creative content, as well as text links, coupon codes, and special Data Feeds to help Affiliates bring business to the CannazALL™ site. In addition, the Company will be creating custom Affiliate programs and creatives for its larger Affiliate partnerships.

Chief Marketing Officer, Frank Casella said 

"The company is currently in negotiations with several large, high traffic partners to complement the addition of the many new Affiliates who have embraced the new CannazALL™ product line, generous commission structures, exciting new creatives and incentive programs. We have already seen increased traffic and sales as a result, which is a terrific sign of things to come, both in the short term and for the foreseeable future"

Nationally Esteemed Law Firm Burns & Levinson to Provide Simplifya’s Market Guide with Comprehensive, Up-to-Date Finance and Lending Regulatory Expertise for All 50 States

 Simplifya (“Simplifya” or “the Company”), the leading regulatory and operational compliance software platform serving the cannabis industry, formed a relationship with Burns & Levinson, an award-winning national law firm with nearly a decade of experience in the cannabis industry. Burns & Levinson will provide real-time finance and lending regulatory guidance to Simplifya Market Guide, a new RegTech platform that arms cannabis and cannabis-related businesses with comprehensive, user-friendly regulatory summaries for all 50 states.

“We created Simplifya Market Guide to provide easy-to-read state-by-state summaries that are regularly updated, and include information about every vital topic related to regulation,” said Simplifya CEO and Co-Founder Marion Mariathasan.

“As one of cannabis’ legal trailblazers, Burns & Levinson’s expertise in cannabis lending and financial regulations is unrivaled. By bringing the best finance and lending guidance to cannabis license holders and marijuana-related businesses (“MRBs”), our real-time RegTech platform simplifies the complex.”

"By bringing our finance and lending guidance to Simplifya Market Guide, we are delivering key due diligence content that is critical to understanding state-specific regulations for lending in the cannabis space, and will inform lenders as to how to compliantly work with licensed businesses in each state,” said Scott Moskol, co-chair of Burns & Levinson’s Cannabis Business & Law Advisory Group.

"Through our relationship, we will also continue to evolve and add essential data for jurisdictions, including those in California.”

LSD has a Cinderella complex

Amanda Feilding, a British countess and drug-reform advocate, is gaining new influence in the psychedelics industry.

Feilding gained notoriety in the 1970s for an experiment where she drilled a hole in her forehead in search of heightened consciousness. Then, in 1998, she created a nonprofit called the Beckley Foundation, which for years has urged the liberalization of drug laws. Her efforts included addressing the United Nations and publishing a 2011 letter calling for a new approach to the war on drugs, signed by more than 60 world leaders and Nobel Prize winners, including former President Jimmy Carter.

Recently, Feilding has been getting into the business side of psychedelics. In 2020, she and her son Cosmo Feilding Mellen co-founded Beckley Psytech, a for-profit company that aims to help patients suffering from psychiatric and neurological disorders by developing psychedelic compounds into licensed drugs. In 2022, she and another son, Rock Feilding-Mellen, started Beckley Retreats, which offers self-development programs that include experiences with psilocybin, or “magic mushrooms,” in places where they can be taken legally, like Jamaica.

Feilding spoke with me last week about her latest projects.

What’s the next thing you’re working on?

I’ve recently put together what I call a two-headed program looking at LSD, which is a Cinderella of the psychedelics party. It’s the purest of the compounds. It’s the beautiful girl that's been left out by her cruel stepmother — which in this case is the government. There was a campaign against LSD in the ’60s and funny enough, people have never got over it. But it’s an incredibly pure and valuable compound for humanity to use.

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorders (the “Company” or “Anebulo”), today announced positive topline data from Part A of an ongoing Phase 2 clinical trial evaluating the potential of ANEB-001 to treat ACI. Part A was a 60 subject randomized, double-blind, placebo-controlled trial designed to evaluate the effectiveness of a single dose of ANEB-001 in treating healthy subjects challenged with delta-9-tetrahydrocannabinol, better known as THC, the primary psychoactive constituent of cannabis. These data demonstrated a highly statistically significant reduction in key symptoms of ACI, with only 10% of subjects in the 50 mg ANEB-001 group and 30% in the 100 mg group reporting feeling high compared to 75% of subjects in the placebo group (p 0.001). ANEB-001 was well tolerated in these healthy volunteers. Preliminary safety information showed all adverse events were mild and transient, except in the case of one subject in the 50 mg ANEB-001 group who experienced moderate nausea and vomiting.

“We believe this proof-of-concept trial demonstrates ANEB-001’s potential to reverse the symptoms of ACI for many of the five thousand cannabinoid intoxicated individuals visiting our emergency departments in the United States on a daily basis,” said Simon Allen, Chief Executive Officer of Anebulo. “We believe marijuana legalization and greater consumer access to cheaper and higher potency THC products will continue to increase the incidence and severity of emergency department visits related to cannabinoid intoxication. With no FDA approved therapy, individuals intoxicated with cannabinoids have few treatment options and may require expensive follow-on interventions for neuropsychiatric complications such as anxiety and acute psychosis. ANEB-001 has the potential to mitigate these unfortunate circumstances and reduce their burden on individuals, society, and our healthcare system.”

The study was conducted at the Centre for Human Drug Research (CHDR) in the Netherlands and enrolled 60 healthy adult occasional cannabis users randomized to three treatment arms of 20 subjects per arm. All subjects were challenged with a single oral dose of 10.5 mg THC and then treated with single oral doses of 50 mg ANEB-001, 100 mg ANEB-001, or placebo. Subjects were monitored for 24 hours to assess safety, tolerability, and pharmacokinetics, and repeatedly tested to determine potential effects on endpoints related to ACI symptoms. The tests also included a series of validated measures of subjective CNS symptoms using visual analog scale (VAS) assessments, as well as objective measures of intoxication. Subjects challenged with THC and treated with placebo showed substantial CNS effects including feeling high, decreased alertness, increased body sway, and increased heart rate. Compared to placebo, treatment of subjects with ANEB-001 led to a significant, robust, and sustained reduction in the VAS feeling high score (p 0.0001 at both dose levels) and improvement in the VAS alertness scale (p 0.01). In addition, the proportion of subjects reporting feeling high on the VAS was significantly reduced by ANEB-001 (p 0.001). Although THC-induced effects on body sway and heart rate in this study were small, there was also a trend towards statistical improvement of these parameters with ANEB-001 treatment compared to placebo. The 50 mg and 100 mg doses had similar results, suggesting that lower doses should be explored. Pharmacokinetic data are pending and additional analyses of Part A data, including pharmacokinetic/pharmacodynamic (PK/PD) correlations, are planned.

“The number of individuals with cannabinoid related intoxication visiting our emergency departments is clearly on the rise,” said Dr. Andrew Monte M.D., Ph.D., Professor of Emergency Medicine & Medical Toxicology, University of Colorado Denver-Anschutz Medical Center. “Patients are coming from multiple settings including first-time users taking small doses of THC, adults and children inadvertently ingesting powerful THC gummies, and regular users unintentionally overdosing on new and more powerful THC products. Introducing an effective cannabinoid antidote into our treatment options would represent a significant improvement in how we can manage these patients”

About Acute Cannabinoid Intoxication (ACI)

Symptoms of ACI can include increased somnolence, impaired cognition and perception, disorientation, anxiety, and acute psychosis. According to DSM-5, a diagnosis of cannabinoid intoxication should include recent history of cannabinoid use, clinically considerable behavioral or psychological changes, such as euphoria, impaired judgment and motor skills, which have taken place since cannabinoid exposure.

BC has become well known over the last few decades for its craft cannabis production. The legacy of top-quality cannabis is possible thanks to the operation tactics, methods, and protocols carried through legalization.

Take trimming, for example. Properly trimmed cannabis isn’t a must for the plants’ survival.

However, trimming influences the cannabis’ final form, dry curing process, and potency. If fan leaves and stray structures from the desired form of a calyx are left uncared for, they can be susceptible to undesirables such as mold.

Cannabis concessioners have preferred hand-trimmed over machine-trimmed due to the risk of aggressive machinery depleting trichome integrity in an already delicate process. Cannabis is a collaborative industry; sometimes, hiring a qualified team to step in to complete the task is easier.

In BC, two main teams specialize in trimming and plant care: Green Team Solutions and BC Trimmers.

Green Team Solutions overview

Green Team Solutions offer trimming, harvesting, pruning, bucking, planting, packaging, cleaning, pre-rolls, cloning, Analytics Data Input (trained on multiple seed-to-sale software programs), consulting, and training

Geographically, the APAC industrial hemp market is predicted to witness the fastest growth during 2021–2030

The value of the industrial hemp market in 2021 was $,4452.0 million, and with a CAGR of 33.7% from 2021 to 2030, it is expected to reach $60,682.8 million. Hemp belongs to the same flora species as cannabis. The only distinguishing feature is that it contains low levels of tetrahydrocannabinol (THC). According to the U.S. 2018 farm law, hemp is not considered cannabis if it contains 0.3% or less THC.

Hemp cultivation is permitted in 36 countries globally, and the crop is expected to cater to the increasing bast fiber demand for high-quality textiles. Selling hemp and hemp products is legal in the U.S., as numerous states have legalized its farming. Moreover, Canada has focused on hemp cultivation for seed production, as it is widely used in the food and cosmetics industries. Recently, it also started to utilize this crop for building materials, insulation, and composites. China exports hemp fibers to Europe and Northern America.

Since the legalization of industrial hemp cultivation, a surge in the industrial hemp market size is being witnessed. In the U.S., hemp with less than 0.3% THC has been removed from the controlled substances definition. Similarly, the cultivation of cannabis varieties with less than 0.2% THC is legal in the European Union. The Chinese National Anti-Drug Committee also announced in 2019 that CBD is not a controlled drug anymore and removed it from the narcotic drugs list. Further, cannabis with 0.3% or less THC can be grown in certain regions of China.

The food industry dominated the industrial hemp market in 2021, accounting for more than 25% share. Hemp is utilized as a source of fiber and oil seeds in various industrial products. That’s why industrial hemp is grown as an agricultural commodity in more than 25 countries. For more than 5,000 years, hemp seeds and oil have been used in the human diet in APAC and Europe. Butter pastes, non-dairy milk, non-dairy cheeses, non-soy tofu, salad oils, and health bars are the major food products with hemp seeds and hemp oil.

The burgeoning usage of hemp in the pharmaceutical industry is a major industrial hemp market growth driver. There are numerous benefits of hemp, which allows it to be used to treat and mitigate various health conditions. Hemp contains a favorable omega-6-to-omega-3-PUFA ratio, which provides support in the treatment of cardiovascular diseases, lessens osteoporosis symptoms, and alleviates eczema symptoms. Moreover, CBD serves as an agent for the treatment of illnesses of the central nervous system, including epilepsy, multiple sclerosis, and neurodegenerative diseases.

lobal Cannabis Applications Corp. ("GCAC" or the "Company") (CSE:APP), (FSE:2FA), (OTC:FUAPF), a leading blockchain driven compliance and data platform announce that Bio-Sunn Technologies Inc.  (“Bio-Sunn”) and GCAC have entered into a Letter of Intent  (“LOI”) that enables processor Bio-Sunn to work with industrial and CBD hemp growers to develop premium products on a sustainable and transparent supply chain using the Company’s “Efixii” and “clearESG” software. The Definitive Agreement is to be signed no later than July 31, 2022.

In the LOI, Bio-Sunn represents it will be processing hemp for 1,000 farmers and distributors in 20 States and Canada through its production facility in North Dakota.  To capture the data from the hemp supply chain, Bio-Sunn will acquire a Resale and a License to Use Agreement for the Company's Efixii and clearESG software. As part of Bio-Sunn’s non-exclusive right to resell agreement,  farmers will pay a fee per QR code to use Efixii.  A QR code is generated for farming attestations recorded on a blockchain. clearESG is offered to these farmers, for a monthly fee, to evidence supply chain sustainability reporting. For processing hemp into manufactured products, Bio-Sunn will also pay GCAC for both the use of Efixii and clearESG. Annual licensing fees for each farmer will average USD$2,000 per year for a 3 year contract to the Company. US hemp production was recently valued at USD$824 million in 2021 by the US Department of Agriculture [1].

CEO Bradley Moore stated, "GCAC is a true blockchain-driven supply chain app for agtech. We do three things really well; drive sales of premium products, fix supply chain issues fast and reward great partners who create great products. Our latest tech stack is one of the most advanced layer two Ethereum blockchains available and incredibly robust in helping people run real businesses [2]. This deal with Bio-Sunn is the reason we made Efixii and clearESG.”

Says Lewis Bauer, Bio-Sunn CEO, "As an industry, we are delighted to partner with a technology company that will bring the rural hemp farmers into the conversation, and we will have "real documented ‘farm to table’ stories."

Efixii is licensed to farmers in a SaaS model and is a free-to-use app for industrial hemp and cannabis consumers. Efixii's cannabis data is the intellectual property ("IP ") of GCAC. This IP creates an inherent difficulty in replicating or competing with GCAC's cannabis datasets. GCAC defined their protocols in a provisional US patent application, 'System of Process and Tracking Cannabis Products and Associated Method Using Blockchain’ filed with the USPTO on Dec. 17, 2020.

Akanda Corp. ("Akanda" or the “Company”) (NASDAQ: AKAN), an international medical cannabis platform company, today announced that its UK import and distribution wholly-owned subsidiary CanMart Ltd. (“CanMart”) has partnered with Phlo Connect and Cellen Life Sciences (“Cellen”) to create a first-of-its-kind fully digital dispensing collaboration for medical cannabis. The strategic partnership strengthens CanMart’s existing partnership with Cellen’s digital Leva Clinic and expands its route to market in the UK with a dispensing model that is also fully digital while at the same time improving the experience for UK medical cannabis patients.

Phlo Connect integrates digitally with CanMart, Akanda’s UK-based, fully licensed pharmaceutical importer and distributor, to quickly and conveniently deliver prescriptions to patients throughout the United Kingdom. Initially, patients will secure prescriptions through the Leva Clinic, with product transferred through CanMart to Phlo Connect. Patients can then schedule delivery to their home or office. Phlo Connect is the UK’s leading API driven digital pharmacy infrastructure provider that seamlessly connects prescribers, pharmacies and patients for an end-to-end digital experience. Phlo Connect offers a 120-minute delivery service in London and Birmingham and next-day delivery across the UK. This process will be increasingly seamless for patients in the near future as Phlo Connect, Leva Clinic, and CanMart build additional digital interconnections.

“Akanda is committed to expanding access to high quality products for anyone in need, and that is qualified in the United Kingdom, a growing market for medical cannabis,” commented Tej Virk, CEO of Akanda. “Phlo Connect and Cellen are the ideal partners to make this happen, combining the UK’s first fully digital pharmacy with a digital dispensing model that is easy to use, secure, and real-time. Patients can arrange a specialist consultation and seamlessly connect to Phlo Connect’s smartphone app to arrange medical cannabis delivery. In the nascent UK medical cannabis market, patients currently suffer from excess friction as the prescription process, and last mile delivery is disjointed. We firmly believe that our solution is the best way to satisfy patients and get our 1P and 3P-supplied medical cannabis in their hands quickly and conveniently, which will greatly improve the patient experience.”

“We believe partnering with CanMart and Cellen will be a game-changer for medicinal cannabis patients here in the UK. By integrating with both CanMart and Cellen via our API driven pharmacy platform, we believe that this partnership is the first truly end to end digital experience for medicinal cannabis patients in the UK,” commented Adam Hunter, CCO of Phlo Connect.

Added Eric Bystrom, CEO of Cellen, “Our patients require access to new high-quality products without the friction and hassle of traditional dispensing services. This partnership is another example of our continuing efforts to build on our national, established relationships with the wider pharmaceutical community in innovative ways. We believe that CanMart’s access to high quality products as well as Phlo Connect's extensive capabilities in dispensing will go a long way to helping our service to our patients.”

As the cannabis markets are maturing, we’re seeing new opportunities rise to the surface. JourneyOne Ventures told TechCrunch it’s closed a $10 million fund and has started making its first investments. I spoke with the fund’s solo manager, Helene Servillon, to figure out where the opportunities are in this market.

“There’s only a specific amount of time that I have, until Andreessen Horowitz, First Round Capital and Sequoia Capital are starting to play in this industry. Right now, I don’t have to compete with them, so I want to use that as my advantage,” Servillon told me in an interview, noting that there are other big players in this space, especially on the corporate side of things.

“Boston Beer works in the cannabis industry. PBR is in the cannabis industry, but not everybody is. I want to be a bridge between being a specialist in the industry and the outside world. For me, an emerging fund manager, this is an entry point into venture capital. I chose cannabis because it was the biggest opportunity.”

The fund is dedicated to investing in founders with senior-level executive experience within the cannabis industry. The fund itself counts investors like Elizabeth Yin (general partner at Hustle Fund), Eric Manlunas (general partner at Wavemaker Partners), Fred Kang (former partner at Andreessen Horowitz) and Paul Bowen (founder of Bowen) among its limited partners. The fund proudly points out that more than half of its investors are minorities in the investment space — either women or people of color.

The old, inefficient lighting systems used to cultivate cannabis have long proved problematic. For some time, individuals, regulatory agencies, and state governments have been looking into modern LEDs as the solution to their growing needs

All organic matter needs light to grow and flourish. The source of that light might be the sun, or it might be artificial, but without an abundant and steady supply of light, life withers and never reaches its full potential. Nowhere does this ring truer than in horticulture and farming, specifically the cultivation of a crop that has rocketed in popularity and demand in recent years — cannabis. Sourcing efficient, productive, and affordable LED grow lights for their cannabis plants has been a bone of contention for both commercial and home growers for many a moon. However, courtesy of new lighting technology introduced to the market by innovative tech company Fohse, indoor cannabis growing is a lot easier.

The old, inefficient lighting systems used to cultivate cannabis have long proved problematic. For some time, individuals, regulatory agencies, and state governments have been looking into modern LEDs as the solution to their growing needs. Companies strove in vain to produce LED grow lights that were both efficient and productive until Fohse appeared on the scene and heralded a lighting revolution. Fohse introduced technology to the marketplace that has enabled cultivators, big and small, to replace their old energy and profit sapping light set-ups with state-of-the-art LEDs that utilize less energy and produce higher yields.

Co-founder and CEO of Fohse, Brett Stevens, explained, "The cannabis industry is spreading like wildfire, and any good cannabis product rises and falls on one key aspect — cultivation! Quality cultivation relies on quality lighting, and that's our mission statement. LED is the light that will lead us towards a greener and more energy-efficient future. So it makes perfect sense that Fohse wants to revolutionize one of the fastest growing industries worldwide with a lighting source that is practical, sustainable, efficient, affordable, and, above all, works. Good lighting is the key component to any productive farm. Without it, the farm cannot succeed. It is the integral aspect that no grower can afford to ignore."

As more and more states legalize cannabis and commercial and individual growers get in on the act, Fohse believes their technology will spur the industry they love and have invested so much time into towards a brighter and better future, one LED grow light at a time.

Grow your own weed, leverage your resources, and get inspired by good old Farmville along the way. Do you remember the game? Well, there is something of all that in Hempire. However, instead of farms, the cannabis video game of the moment has flowerpots in the suburbs. And, at the center of everything, marijuana. (Benzinga)

"We wanted to build the best cannabis game in the world," says Canadian Solon Bucholtz about Hempire, the pot video game that he developed with his company LBC Studios.

“Hempire is a passionate project that seeks to de-stigmatize cannabis and present it in an authentic setting rather than typical pot culture,” he continues.

Hempire is a game -half botanical, half strategic simulation- that supports the development of legal cannabis and the benefits it can have on the economy and social relationships.

And Its objective is? Let's say it's simple, diverse, and real: enjoying building a cannabis empire, growing your own strains, communicating, and competing with other growers.

"This is a natural channel extension for us to continue growing our skin care business and meet customers where they are with the products they replenish regularly," said the company's CEO Todd Davis

Endexx Corp said it has received clearance for its hemp-derived and plant-based skincare and grooming products for men in Amazon's store. 

The products are rich in plant-derived nutrients proven to support healthy skin. They have no Cannabidiol or THC in their formulation, providing a clear and compliant pathway to successful e-commerce in the Amazon seller's central platform, the company said. 

The line has been cleared to sell in the USA, Mexico and Canada, with pending approvals in Japan, United Kingdom and Australia. Initially, up to six stock keeping units (SKUs) will be available to consumers. 

"Through customer feedback and research, our consumers want to purchase Endexx products in Amazon's store and already search for the product on the site," said Todd Davis, CEO of Endexx, in a statement.

The store is being professionally built to both optimize key search word success and to maximize the skincare brand's leadership footprint. 

Kandy Girl, a cannabis company that has managed to skirt federal marijuana regulations by selling THC infused edibles in larger sized gummies, announced on Monday, that their app is now live on the Google Play and Apple App Store.

The app allows consumers to purchase their edibles and checkout via credit card or Apple Pay.

The company says Cannabis consumers won't need to provide a medical card and due to the way their gummies are made, they actually contain significantly more THC than dispensary grade gummies.

Kandy Girl isn't subject to statewide marijuana taxes, providing reduced costs for the consumers and saving a trip to the dispensary.

Kandy Girl states that currently, at the time of writing, their gummies are legal in all 50 states despite having 300mg of THC per bottle. That's 3x the statewide legal limit for marijuana edibles sold in a dispensary. Currently, licensed marijuana dispensaries have a cap of 10mg per serving and no more than 100mg per package.

APPlife Digital Solutions, Inc. ( ALDS) (“APPlife”, the Company”), a business incubator and portfolio manager that invests in and creates e-commerce and cloud-based solutions is pleased to announce that the Global Hemp Service LLC (“Global”) web site has recently completed its extended beta period and is now a fully-functioning e-commerce platform that offers an extensive line of hemp and CBD related products including those for personal, home, beauty, organic, and industrial uses.

“We are excited to see the products being offered by Global Hemp Service becoming more prominently featured in daily use around the world. Hemp is a game-changer for its benefits to our climate. APPlife is proud to have been the lead investor in this project and hope to see it flourish in the coming months,” stated Matthew Reid, CEO of APPLife.

"It is our mission at Global Hemp Service to unify hemp stakeholders and support the category growth in all industries where hemp can be applied. The challenge isn't how to make a better world, it’s to make it happen now. Our focus on hemp is the most intelligent decision for us to do our part and reach a sustainable society within a few years," said Paul Iglesia, founder and president of Global Hemp Services LLC.

The team at Global understands that humanity is need of both environmental and societal transformations and while our current resources might be enough, the way we consume them is not sustainable. While cures for these challenges are complicated and will take time, effort, and energy, Global believes part of the cure is a simple plant, created by nature itself, named cannabis, most commonly known as hemp. It’s been interacting with humans all over the planet and the course of history from ancient writings and customs to the present days. There are hundreds of thousands of people all over the planet working with hemp, consuming hemp in their diet, their products, their habitat, and their farms.

Together, APPlife and Global believe that hemp’s diverse applications and attributes could be valuable components in achieving numerous global sustainability goals, some of which include:

Integrating the two best-in-class solutions, Cova and Tymber aim to empower cannabis retailers to focus on efficient in-store and online customer interactions

 Cova Software ("Cova" or "the Company"), a cannabis Point of Sale (POS) software company powering dispensaries across North America, announced the integration of Tymber's eCommerce platform with Cova's award-winning POS and Inventory tracking platform. This integration provides cannabis retailers with a user-friendly platform to offer consumers an on-brand experience with seamless in-store and online shopping options.

The Cova POS and Tymber integration allows cannabis retailers to display accurate product information for online menus, share live inventory updates with online shoppers, build and manage customer profiles, and process transactions with compliance and efficiency.

"Cova's goal is to provide cannabis retailers with beneficial tools to ensure their growth and success," said Gary Cohen, CEO of Cova Software.

"We both understand the importance of retailers being in control of their own customer data and their interactions with their base. Through this Tymber integration, we are aiding dispensaries' ability to grow their business with reliable tools that power dispensary operations and digital growth."

Tymber gives dispensaries an SEO-optimized, eCommerce platform that empowers retailers to break their dependence on iframe menus and 3rd party marketplaces with a recognizable brand and frictionless shopping experience.